Tecan is one of the first companies to meet the requirements of the European Union’s In Vitro Diagnostic Regulation (IVD-R) 2017/746 (Annex IX, Chapter I and III).
The company has successfully completed certification of its IBL International DHEA Saliva ELISA diagnostic assay kit through BSI Notified Body 2797. The valuable insights gained from this process will now be applied to the registration of Tecan’s complete portfolio of specialty IVD products – as well as to help its OEM partners ensure they are ‘IVD-R ready’ – ahead of the May 2022 transition deadline.
The new IVD-R is intended to increase the safety of all IVD products, including all innovations developed over the past decades. It represents a major regulatory overhaul, requiring reclassification and certification of all EU-registered IVD assays and devices.
Introduced in 2017, it extends the scope of the outgoing IVD-Directive (IVD-D) to cover more devices and technologies – as well as supply chain and lifecycle management – and signifies a shift from a primarily ‘self-certification’ model to a requirement for Notified Body (NB) oversight. This greatly increases the regulatory burden for IVD manufacturers and NBs alike, making it essential to begin the certification process as soon as possible to avoid the risk of being forced out of EU markets.
Tecan is recognised as a global leader in quality and regulatory affairs (QARA), and is leading the sector in the management of the IVD-D to IVD-R transition. The company’s position as both an IVD and OEM manufacturer, combined with many years of expertise in IVD product registration globally, means that Tecan is ideally placed to address the challenges of certification for both its own products and those of its partners.
